ONLINE NEWS AND PRINT MEDIA
Have a look at various news about us in media
Through RPG Active Pharma, RPG Life Sciences is investing in the future of high-value APIs with a commitment of up to ₹700 crore to expand manufacturing capabilities, strengthen its product portfolio, and unlock new growth opportunities in global markets.
Building a Scalable API Platform for the Future
RPG Life Sciences partners with InvAscent to accelerate growth through dedicated capital, expanded capabilities, and strategic acquisitions in the API business
RPG Life Sciences has established RPG Active Pharma as a dedicated API platform and partnered with healthcare-focused investor InvAscent to accelerate growth, expand capabilities, and strengthen its position in the API manufacturing space.
RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.
Ashok Nair, managing director, RPG Life Sciences, said:
"Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands.
Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness."
Ashok Nair, MD of RPG Life Sciences said the company delivered strong revenue and profit growth, with expansion across therapy areas and stable margins expected going forward, supported by pricing actions and business expansion.
The board of RPG Life Sciences Technologies has recommended a dividend of ₹24 per equity share, or 300 per cent on the face value of ₹8 per share, fully paid up, for FY26
Bajaj Finance share price rose 4 percent after reporting a strong operational performance, with its Q4 consolidated profit rising 22 percent year-on-year to Rs 5,553 crore.